Multiple Myeloma Clinical Trials

Find Multiple Myeloma Clinical Trials Near You

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Multiple myeloma patient:

• ≥ 18 years old

• ≥ 1 prior lines of therapy

• Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)

• On previous Ig support or not

Locations
Other Locations
Canada
Centre Intégré de Cancérologie
RECRUITING
Québec
Contact Information
Primary
Philippe Nadeau, PhD
philippe.nadeau@chudequebec.ca
1-418-525-4444
Time Frame
Start Date: 2026-01-05
Estimated Completion Date: 2029-12
Participants
Target number of participants: 80
Treatments
Active_comparator: Group A IgG level 8-10 g/L
Immunoglobulin support (subcutaneous or intravenous)
Experimental: Group B IgG level 4-6 g/L
Immunglobulin support (subcutaneous or intravenous)
Other: Group C
No immunoglobulin support. If pre specified conditions are met, crossover to Group A or B.
Related Therapeutic Areas
Multiple Myeloma
Sponsors
Leads: CHU de Quebec-Universite Laval

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

Enrollment Status: Recruiting
Publish Date: April 24, 2025
Intervention Type: Drug
Study Phase: Phase 2

Pragmatic Geriatric Assessment (pGA) Before Bispecific Antibody and CAR-T-Cell Therapy (GA-ACT Trial) for the Prediction of Toxicity and Outcomes in Older Patients Scheduled for Chimeric Antigen Receptor T-Cell Therapy (CAR-T-Cell-Therapy) or Bispecific Antibody (bsAB) Treatment

Pragmatic Geriatric Assessment (pGA) Before Bispecific Antibody and CAR-T-Cell Therapy (GA-ACT Trial) for the Prediction of Toxicity and Outcomes in Older Patients Scheduled for Chimeric Antigen Receptor T-Cell Therapy (CAR-T-Cell-Therapy) or Bispecific Antibody (bsAB) Treatment

Enrollment Status: Recruiting
Publish Date: December 30, 2025
Intervention Type: Other

Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Phase 1b Study to Assess Safety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Enrollment Status: Recruiting
Publish Date: February 02, 2026
Intervention Type: Procedure, Biological, Drug
Study Phase: Phase 1
View All